Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic

Benesh, Gabrielle; Andriano, Tyler M.; Babbush, Kayla M.; Hosgood, H. Dean; Cohen, Steven R.

doi:10.1177/1203475421997058

Cited by 5 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, we report the most recent data from the Global Hidradenitis Suppurativa COVID-19 Registry, which further demonstrate that HS patients on biologics do not have higher odds of hospitalization or require respiratory support compared to those on nonbiologic therapies. Although previous studies of smaller HS cohorts have reported similar findings [ 1 , 2 ], the findings from this report, which includes 126 cases (105 self/caregiver-reported and 21 HCP-reported) that were reported after the introduction of COVID-19 vaccines, are notable given that anti-TNF therapy is associated with faster declines in COVID-19 vaccine-induced neutralizing antibodies in patients with chronic inflammatory diseases [ 3 ].…”

supporting

confidence: 54%

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

et al. 2022

View full text Add to dashboard Cite

supporting

confidence: 54%

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

et al. 2022

View full text Add to dashboard Cite

“…Our systematic search of the literature allowed us to identify 37 case reports and case series 20‐56 and 11 studies that corresponded to our research question but their data were provided descriptively and an effect measure could not be calculated 21,57‐66 . These data are included in Table S1.…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments

Kokkotis

Kitsou

Xynogalas

et al. 2021

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Accumulating evidence suggests a beneficial effective of tumour necrosis factor‐alpha (TNF‐α) inhibitors on the outcomes of COVID‐19 disease, which, however is not validated by all studies. Aims To perform a systematic review and meta‐analysis of existing reports to investigate the impact of anti‐TNF treatments on the clinical outcomes of COVID‐19 patients. Methods A systematic search at PubMed and SCOPUS databases using specific keywords was performed. All reports of COVID‐19 outcomes for patients receiving anti‐TNF therapy by September 2021 were included. Pooled effect measures were calculated using a random‐effects model. The Newcastle Ottawa Scale for observational studies was used to assess bias. Studies that were not eligible for meta‐analysis were described qualitatively. Results In total, 84 studies were included in the systematic review, and 35 were included in the meta‐analysis. Patients receiving anti‐TNF treatment, compared to non‐anti‐TNF, among COVID‐19 cases had a lower probability of hospitalisation (eight studies, 2555 patients, pooled OR = 0.53, 95% CI: 0.42‐0.67, I2 = 0) and severe disease defined as intensive care unit admission or death (two studies, 1823 patients, pooled OR = 0.63, 95% CI: 0.41‐0.96, I2 = 0), after adjustment for validated predictors of adverse disease outcomes. No difference was found for the risk for hospitalisation due to COVID‐19 in populations without COVID‐19 for patients receiving anti‐TNF treatment compared to non‐anti‐TNF (three studies, 5 994 958 participants, pooled risk ratio = 0.97, 95% CI: 0.68‐1.39, I2 = 20) adjusted for age, sex and comorbidities. Conclusions TNF‐α inhibitors are associated with a lower probability of hospitalisation and severe COVID‐19 when compared to any other treatment for an underlying inflammatory disease.

show abstract

“…[ 76 ] Neither are the outcomes or risk of COVID-19 infection increased in HS patients treated with Tumor necrosis factor-a inhibitors. [ 77 78 80 ] Such observations were made despite the fact that the PIONEER I and II studies highlighted a slightly increased risk for upper respiratory tract infections and nasopharyngitis in HS patients treated with adalimumab versus the placebo group. [ 81 ] While HS patients are weary of immunomodulation in the setting of a global pandemic, it appears that they are comfortable with continuing the medication to maintain disease control.…”

Section: Discussionmentioning

confidence: 99%

Clinical Dermatology and COVID-19 Pandemic

Mintoff

Chatterjee

Podder

et al. 2021

Indian Journal of Dermatology

View full text Add to dashboard Cite

The coronavirus disease of 2019 (COVID-19) pandemic has radical repercussions on every aspect of medical science, including dermatology. The magnitude of the impact on clinical dermatology cannot be overemphasized. Dermatologists have been forced to modify and reconsider the way they consult patients. Teledermatology has come up in a big way, with most of the clinicians resorting to technology and software-based consultations. Management of different dermatological conditions like papulosquamous disorders, vesiculobullous disorders, malignancies, etc., needs to be modified as per the different recommendations proposed by expert panels. This review is an attempt to highlight the impact of this destructive pandemic on various aspects of clinical dermatology.

show abstract

Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic

Cited by 5 publications

References 5 publications

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments

Clinical Dermatology and COVID-19 Pandemic

Contact Info

Product

Resources

About